Balchem (CH:BL9B)
NASDAQ:BL9B
BL9B Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageMaterial reduction in leverage and rising equity provide financial flexibility to fund capex, M&A, and working capital without stressing liquidity. Low net leverage (~0.3 reported) and healthy cash balances reduce refinancing risk and support durable investment in growth initiatives over 2–6 months.
Sustained Margin ExpansionConsistent gross and operating margin expansion reflects structural gains from higher‑margin product mix, manufacturing efficiencies and pricing power. Sustained margin improvement underpins durable earnings quality and frees cash for reinvestment, making profitability less sensitive to short swings.
Strong Cash Generation And FCFOperating cash flow consistently above net income and improving free cash flow conversion provide a durable source of internal funding. Reliable cash generation supports dividends, debt reduction and strategic investments, lowering reliance on external finance over the medium term.
Bears Say
Input-cost Inflation RiskPetrochemical-driven raw material inflation can be structural for segments tied to commodity inputs and may cause persistent margin pressure until passthrough to customers occurs. Repeated cost shocks could compress margins and force recurring price negotiations or product mix shifts over several quarters.
Historically Uneven Revenue GrowthA history of choppy top-line performance indicates revenue is sensitive to end-market demand cycles and mix shifts. Even with a recent rebound, inconsistent growth raises execution risk for sustaining investment-led expansion and makes forward planning for capacity and margins more uncertain over the medium term.
Rising Operating ExpensesHigher fixed operating costs tied to sales, hiring and professional services can limit operating leverage if revenue growth slows. If investments take longer to generate returns, elevated OPEX may erode margin gains and cash flow resilience over multiple quarters, increasing execution risk.
Balchem News
BL9B FAQ
What was Balchem’s price range in the past 12 months?
Currently, no data Available
What is Balchem’s market cap?
Balchem’s market cap is CHF4.21B.
When is Balchem’s upcoming earnings report date?
Balchem’s upcoming earnings report date is Jul 24, 2026 which is in 38 days.
How were Balchem’s earnings last quarter?
Balchem released its earnings results on Apr 30, 2026. The company reported $0.979 earnings per share for the quarter, beating the consensus estimate of $0.975 by $0.004.
Is Balchem overvalued?
According to Wall Street analysts Balchem’s price is currently Undervalued.
Does Balchem pay dividends?
Balchem does not currently pay dividends.
What is Balchem’s EPS estimate?
Balchem’s EPS estimate is 1.02.
How many shares outstanding does Balchem have?
Currently, no data Available
What happened to Balchem’s price movement after its last earnings report?
Balchem reported an EPS of $0.979 in its last earnings report, beating expectations of $0.975. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Balchem?
Currently, no hedge funds are holding shares in CH:BL9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Balchem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.32%
12-Months-Change
Fundamentals
Return on Equity
12.38%
Trailing 12-Months
Asset Growth
4.71%
Trailing 12-Months
Company Description
Balchem
Balchem Corporation specializes in the creation, production, and distribution of high-performance specialty ingredients and solutions, catering to diverse sectors including human and animal nutrition, food and pharmaceuticals, medical device sterilization, agricultural plant health, and various industrial applications, operating both domestically and globally. The company organizes its operations into three primary divisions: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment primarily serves the food and beverage industry with essential ingredients. Its extensive product portfolio encompasses spray-dried and emulsified powders, extrusion and agglomeration technologies, specialized lipid blends, liquid flavor delivery solutions, various bases for juices, dairy, chocolate, and cereals, alongside ice cream bases and variegates. Additionally, this segment provides microencapsulation technologies for diverse uses, in addition to human-grade choline nutrients and chelated mineral amino acid products vital for health and wellness. The Animal Nutrition & Health segment delivers microencapsulated products designed to boost the health and milk yield of ruminant animals, while also supplying nutrient supplements. It also leverages chelation technology to improve nutrient absorption across a wide range of production and companion animal species, and offers choline chloride, a key nutrient for the health of monogastric animals. The Specialty Products segment is a supplier of ethylene oxide (EtO), primarily utilized for sterilization within the healthcare sector, including single-use canisters for sterilizing reusable medical devices. Furthermore, it markets propylene oxide, a fumigant effective in controlling insects, microbial spoilage, and reducing bacterial and mold contamination in a variety of food products such as nuts (shelled and processed), spices, cacao beans, cocoa powder, and dried fruits like raisins, figs, and prunes. The segment also provides chelated minerals tailored for high-value agricultural crops. Balchem distributes its offerings through a combination of its direct sales force, independent distributors, and dedicated sales agents. Established in 1967, Balchem Corporation maintains its headquarters in New Hampton, New York.
BL9B Company Deck
BL9B Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple record financial metrics (revenue, adjusted EBITDA, adjusted EPS, gross margin dollars) and showcased broad-based growth across all three segments, strong cash generation, improved margins, sustainability achievements, and promising branded-ingredient progress (notably Vidacholine). Headwinds include emerging petrochemical-driven inflation, higher operating expenses tied to growth investments, and geopolitical-related supply-chain/freight risk that could cause modest margin compression in the near term. Overall, the positive operational and financial momentum, coupled with manageable leverage and clear strategic initiatives, outweigh the noted risks.View all CH:BL9B earnings summariesBL9B Stock 12 Month Forecast
Average Price Target
$168.76
Options Prices
Currently, No data available
---